Dr. Reddy's Labs ADR had its Relative Strength (RS) Rating upgraded from 68 to 73 Wednesday — a welcome improvement, but still short of the 80 or higher score you prefer to see.
Can You Really Time The Stock Market?
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks tend to have an 80 or higher RS Rating as they begin their largest runs. See if Dr. Reddy's Labs ADR can continue to show renewed price strength and clear that threshold.
Dr. Reddy's Labs ADR is trying to complete a consolidation with a 16.89 entry. See if it can clear the breakout price in heavy trading.
Dr. Reddy's Labs ADR saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 16%. Revenue rose from 13% to 17%. The company is expected to report its latest earnings and sales numbers on or around Jul. 23.
Dr. Reddy's Labs ADR earns the No. 1 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals and Collegium Pharmaceutical are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
